Dean Regier

Dr. Dean Regier


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Value in Health
Verified
Journal Article
Closed access
JBJohn F.P. Bridges
John F.P. Bridges
AHA. Brett Hauber
A. Brett Hauber
DMDeborah A Marshall
Deborah A Marshall
ALAndrew Lloyd
Andrew Lloyd
LPLisa A. Prosser
Lisa A. Prosser
JMJosephine Mauskopf
Josephine Mauskopf

1 January 2013 in Value in Health
Verified
Journal Article
Closed access
FJF. Reed Johnson
F. Reed Johnson
ELEmily Lancsar
Emily Lancsar
DMDeborah A Marshall
Deborah A Marshall
VKVikram Kilambi
Vikram Kilambi
AMAxel Mühlbacher
Axel Mühlbacher
JBJohn F.P. Bridges
John F.P. Bridges

1 January 2005 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
MCMirella De Civita
Mirella De Civita
DRDean Regier
Dean Regier
AAAbul H. Alamgir
Abul H. Alamgir
AAAslam H. Anis
Aslam H. Anis
MFMark J. FitzGerald
Mark J. FitzGerald
CMCarlo A Marra
Carlo A Marra

13 April 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
EPErin Pleasance
Erin Pleasance
ETEmma Titmuss
Emma Titmuss
LWLaura Williamson
Laura Williamson
HKHarwood Kwan
Harwood Kwan
LCLuka Culibrk
Luka Culibrk
MMMarco Marra
Marco Marra

9 March 2015 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
DRDean Regier
Dean Regier
Stuart PeacockStuart Peacock
Stuart Peacock
RPReka Pataky
Reka Pataky
KHKimberly van der Hoek
Kimberly van der Hoek
GJGail P. Jarvik
Gail P. Jarvik
DVDavid Veenstra
David Veenstra
Background: An important challenge with the application of next-generation sequencing technology is the possibility of uncovering incidental genomic findings. A paucity of evidence on personal utility for incidental findings has hindered clinical guidelines. Our objective was to estimate personal utility for complex information derived from incidental genomic findings. Methods: We used a discrete-choice experiment to evaluate participants’ personal utility for the following attributes: disease penetrance, disease treatability, disease severity, carrier status and cost. Study participants were drawn from the Canadian public. We analyzed the data with a mixed logit model. Results: In total, 1200 participants completed our questionnaire (available in English and French). Participants valued receiving information about high-penetrance disorders but expressed disutility for receiving information on low-penetrance disorders. The average willingness to pay was $445 (95% confidence interval [CI] $322–$567) to receive incidental findings in a scenario where clinicians returned information about high-penetrance, medically treatable disorders, but only 66% of participants (95% CI 63%–71%) indicated that they would choose to receive information in that scenario. On average, participants placed an important value ($725, 95% CI $600–$850) on having a choice about what type of findings they would receive, including receipt of information about high-penetrance, treatable disorders or receipt of information about high-penetrance disorders with or without available treatment. The predicted uptake of that scenario was 76% (95% CI 72%–79%). Interpretation: Most participants valued receiving incidental findings, but personal utility depended on the type of finding, and not all participants wanted to receive incidental results, regardless of the potential health implications. These results indicate that to maximize benefit, participant-level preferences should inform the decision about whether to return incidental findings.

17 October 2011 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
PDF file
DTDeborah Tomlinson
Deborah Tomlinson
UBUte Bartels
Ute Bartels
JGJanet Gammon
Janet Gammon
PHPamela S. Hinds
Pamela S. Hinds
JVJocelyne Volpe
Jocelyne Volpe
LSLillian Sung
Lillian Sung
Background: The choice between palliative chemotherapy (defined as the use of cytotoxic medications delivered intravenously for the purpose of our study) and supportive care alone is one of the most difficult decisions in pediatric oncology, yet little is known about the preferences of parents and health care professionals. We compared the strength of these preferences by considering children’s quality of life and survival time as key attributes. In addition, we identified factors associated with the reported preferences. Methods: We included parents of children whose cancer had no reasonable chance of being cured and health care professionals in pediatric oncology as participants in our study. We administered separate interviews to parents and to health care professionals. Visual analogue scales were shown to respondents to illustrate the anticipated level of the child’s quality of life, the expected duration of survival and the probability of cure (shown only to health care professionals). Respondents were then asked which treatment option they would favour given these baseline attributes. In addition, respondents reported what factors might affect such a decision and ranked all factors identified in order of importance. The primary measure was the desirability score for supportive care alone relative to palliative chemotherapy, as obtained using the threshold technique. Results: A total of 77 parents and 128 health care professionals participated in our study. Important factors influencing the decision between therapeutic options were child quality-of-life and survival time among both parents and health care professionals. Hope was particularly important to parents. Parents significantly favoured chemotherapy (42/77, 54.5%) compared with health care professionals (20/128, 15.6%; p < 0.0001). The opinions of the physician and child significantly influenced the parents’ desire for supportive care; for health care professionals, the opinions of parents and children were significant factors influencing this decision. Interpretation: Compared with health care professionals, parents more strongly favour aggressive treatment in the palliative phase and rank hope as a more important factor for making decisions about treatment. Understanding the differences between parents and health care professionals in the relative desirability of supportive care alone may aid in communication and improve end-of-life care for children with cancer.